Duchenne Muscular Dystrophy (DMD) is an X-linked neuromuscular disorder char acterized by progressive muscle de-generation in young male populations. Current therapeutic strategies function as symptom-mitigating agents rather than definitive cures, highlighting the urgent need for novel and more effective treatments. The recent FDA-approval of the first gene therapy, based on adeno-associated viruses (AAVs) delivering the micro-dystrophin gene, to restore protein function, brought a lot of optimism. However, important limitations remain, including the requirement for high vector doses, off-target liver accumulation, and, most importantly, immune recognition of the viral capsids. For this aim, a surface-tethering strategy was employed, using a two-step re action process.